DET

Discovery

DET was first synthesized by Stephen Szára in Budapest in 1956 as part of a systematic investigation of tryptamine derivatives.^[1][7] The first formal clinical study, published in 1959, administered DET to institutionalized psychiatric patients under coercive conditions — which likely explains the predominantly anxious responses observed.^[3][5]

Clinical and cultural significance

DET's investigation was part of the mid-twentieth-century wave of European psycholytic therapy research, when tryptamines and lysergamides were explored as psychiatric tools.^[8] Early studies found its effects broadly similar to but milder than LSD.^[7] Alexander Shulgin documented it as entry #3 in TiHKAL (1997), providing synthesis routes and collected experience accounts.^[5]

Prohibition and modern status

DET was placed on Schedule I of the 1971 UN Convention on Psychotropic Substances — one of only five tryptamines under international control, alongside DMT, etryptamine, psilocin, and psilocybin.^[4] No modern controlled clinical trial has been initiated. It remains a historical footnote — one of the earliest tryptamines characterized in humans, yet among the least studied in the contemporary research renaissance.

Structural class

DET belongs to the N,N-dialkyltryptamine family — the same structural family as DMT, differing only in having two ethyl groups on the nitrogen where DMT has two methyl groups.^[9] Those larger groups slow its breakdown in the gut and liver, making DET orally active without MAOI co-administration.^[1]

This N,N-dialkyl substitution pattern is critical for psychedelic activity at serotonin receptors.^[10] Its molecular formula is C₁₄H₂₀N₂ (molecular weight 216.32 g/mol); it has no chirality centers — it exists as a single form.^[9]

Physical properties

Physical property data derive from Shulgin's documentation^[5] and secondary sources.^[1]

Mechanism of action

DET works primarily by activating serotonin receptors in the cortex.^[2] This activation — specifically through the Gq-coupled signaling pathway — is what drives the psychedelic response.^[11] DET is orally active without MAOI co-administration, unlike DMT — the ethyl groups on its nitrogen slow gut-and-liver breakdown enough for it to reach the brain intact.^[1]

Pharmacokinetics

No formal pharmacokinetic study has been published for DET. Oral onset takes 30–90 minutes, with peak effects at 2–4 hours and after-effects lasting up to 8 hours.^[5][9] Oral bioavailability was confirmed in the earliest clinical investigations.^[7]

The body breaks DET down primarily through MAO-A oxidative breakdown. One metabolite — 6-hydroxy-DET — has minor psychoactive activity, which is notable because the equivalent DMT metabolite is inactive.^[5] Half-life, plasma concentrations, and clearance remain uncharacterized in humans.^[12] safety citation needed

Where it acts

No brain imaging or electrophysiology studies have been published for DET. As a serotonin receptor activator, it is expected to act on cortical neurons, disrupting the brain's default resting network and reducing its usual filtering of sensory input. citation needed The resulting signaling cascade modulates glutamate activity and cortical excitability, producing the characteristic disruption of ordinary perception.^[11]

Why it matters

The dominant theoretical framework — called the REBUS model — holds that serotonin receptor activation reduces how strongly top-down predictions shape perception, allowing raw sensory input more influence. citation needed This predicts DET's reported visual generation, looser associative thinking, and softened sense of self at higher doses. Whether DET specifically promotes brain plasticity has not been investigated, though its serotonin receptor activity makes such effects plausible. citation needed

Toxicity

No lethal dose has been established for DET in any species, and no human fatality attributable to the compound has been reported. safety citation needed This absence reflects how uncommon the compound is, not confirmed safety.

Psychological risks

Acute anxiety and psychosis-like states were documented in early studies using institutionalized patients under coercive conditions.^[3] Those conditions likely amplified negative responses rather than revealing a property inherent to DET. Anxiety, paranoia, and thought loops are reported, particularly without appropriate preparation or environment.^[3][5]

Lingering visual disturbances after the experience — called HPPD — have not been specifically reported for DET but are a documented class-level risk for serotonergic psychedelics. DET may also precipitate latent psychosis in individuals with personal or family history of psychotic disorders.

Tolerance and dependence

Tolerance builds effectively after a single dose — serotonin receptors in the frontal cortex downregulate rapidly.^[6] Cross-tolerance with all classical psychedelics (LSD, psilocybin, DMT, mescaline) is expected.^[6] inferred Community estimates place tolerance half-life at approximately 3 days, with full reset at approximately 7 days.

Classical psychedelics do not produce physical dependence or withdrawal. Animal studies have consistently failed to show compulsive self-administration with serotonergic psychedelics.^[14]

Drug interactions

The most significant interaction risks are serotonergic.^[15]

Irreversible MAOIs (phenelzine, tranylcypromine) combined with DET create serious serotonin syndrome risk — the MAOIs block the enzyme that breaks down DET, dramatically elevating systemic exposure.^[15]

Reversible MAOIs (moclobemide, harmaline) carry moderate risk through increased duration, intensity, and additive serotonergic load.^[15]

SSRIs present dual risk: serotonin toxicity and unpredictable modulation of the experience — either blunting or paradoxical intensification.^[15]

Lithium is a class-level contraindication, with case reports of seizures and heart rhythm disturbances. citation needed

Tricyclic antidepressants carry additive serotonergic risk.

No DET-specific drug interaction studies have been published. All interaction data are class-level inferences.

Contraindications

Contraindications are inferred from the serotonergic psychedelic class. No substance-specific data exist. inferred

• Psychotic disorders (schizophrenia, schizoaffective disorder): serotonin receptor activation may trigger or worsen psychotic episodes. Absolute contraindication.
• Bipolar disorder with psychotic features: risk of manic or psychotic episode. Absolute contraindication.
• Family history of psychotic disorders: elevated risk of psychosis precipitation. Relative contraindication.
• Current lithium therapy: documented seizure and heart rhythm risk. Absolute contraindication.
• Current MAOI therapy: serotonin syndrome risk. Absolute contraindication.
• Current SSRI therapy: unpredictable interaction and serotonin toxicity risk. Relative contraindication.
• Heart conditions: elevated heart rate and blood pressure documented clinically. Relative contraindication.

DET is one of only five tryptamines under international control, listed in Schedule I of the 1971 Convention on Psychotropic Substances.^[4] National implementations vary — some jurisdictions explicitly name DET, while others rely on structural analog provisions.

Analogue act considerations

The United States does not explicitly list DET in the Controlled Substances Act. The Federal Analogue Act treats compounds "substantially similar" to a Schedule I substance as Schedule I if intended for human consumption — and given DET's structural similarity to DMT, prosecution under that Act is plausible. This ambiguity does not mean DET is legal in the United States. citation needed